Interventional effect of compound Qingrekeli on the expression of human leukocyte antigen DR in lymphocyte of patients with postoperative pneumonia after renal transplantation

Huang Y,Hong Wang,ShuWen Zhang,Baoen Wang
2007-01-01
Abstract:AIM: To observe the dynamic changes in human leukocyte antigen DR (HLA-DR) antigen presentation on peripheral blood lymphocyte (PBL) of patients with postoperative pneumonia after renal transplantation and the curative efficacy of compound Qingrekeli. METHODS: Thirty-two patients with postoperative pneumonia after renal transplantation were selected from the Clinic of Infection, Beijing Friendship Hospital from January 2005 and February 2006, and all patients knew and agreed with the items. Subjects were randomly divided into 2 groups: ① Western medicine group (n =18): Patients were treated with western medicine for anti-infection and immune suppression. ② Integrative treatment of Chinese medicine and western medicine group (integrative group, n =14): Patients were treated the same as those in western medicine group plus orally taken Qingrekeli (manufactured by Shouchuang Dadi Pharmaceutical Co., Ltd with the main components of: 30 g of Pugongying, 30 g of Baijiangcao, 30 g of Shenghuangqi, and 6 g of Dahuang) once a pack, three times a day for 14 days. HLA-DR in blood was determined respectively at 7 and 14 days after the treatment, so as to obtain the activation of T-cells. The effect was evaluated at 14 days post treatment: The temperature decreased with symptoms of respiratory tract ameliorated, and X-ray showed that the focus of infection was ameliorated. RESULTS: Thirty-two enrolled patients with postoperative pneumonia after renal transplantation were involved in the analysis of results, and no one withdrew from the study. ① Comparison in the improvement rate between the two groups: It was better in the integrative group than that in the western medicine group, while the differences were not significant (93%,78%,P > 0.05). ② Comparison in the percentage of HLA-DR antigen positive cells on PBL between the two groups: It was significantly higher in integrative group at 14 days after the treatment than that in the western medicine group [(48.87±1.98) %, (36.56±2.43) %, P < 0.05], and it was remarkably higher than that in patients while hospitalization [(33.89±1.45)%, P < 0.05]. CONCLUSION: Compound Qingrekeli can up-regulate the expression of HLA-DR in PBL of patients with postoperative pneumonia after renal transplantation.
What problem does this paper attempt to address?